12:00 AM
 | 
May 15, 2000
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Immune Network Research Ltd., Meditech Pharmaceuticals Inc. preclinical data

The companies said that preliminary in vitro efficacy tests indicate that MTCH-24 is active against both HSV-I and HSV-II and is less cytotoxic than...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >